Quantcast
Last updated on April 19, 2014 at 1:20 EDT

CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding

December 19, 2012

WOBURN, Mass., Dec. 19, 2012 /PRNewswire/ — CutisPharma, Inc. today announced that the United States Patent and Trademark Office has issued a patent (US 8,276,757 B2) regarding a method for the preparation, storage and dispensing of compounded suppositories. The FIRST(®) container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. The FIRST(®) suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient patient dispensing.

“The goal for CutisPharma and our FIRST(® )Kits is to meet the “Golden Rule” of compounding, which is one Rx from one prescriber for one patient, and our FIRST(® )Kits will help pharmacies meet this goal,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “The use of FIRST(®) Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>,” he added.

It is estimated that each year in the United States approximately 40 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

FIRST(®) products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST(®) Kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits, and three lansoprazole suspension kits. Several more compounding kits are in the planning stages.

About CutisPharma
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 13 million currently compounded prescriptions, by offering FIRST(®) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Four U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com

SOURCE CutisPharma, Inc.


Source: PR Newswire